Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Wealth planning tools are essential for financial success. Discover resources that can help you achieve your financial aspirations.
28,655 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Oil prices jumped above $100 a barrel as YieldMax’s XOMO ETF continued to pay weekly distributions fed by option prem...
SanDisk moved down about 5% after reporting strong Q4 results, fueling a sharp debate on whether the AI-led rally in ...
Tether converts a historic $13 billion profit into a bold health-tech investment, backing Eight Sleep at a $1.5 billi...
After a sharp early-2026 retreat, Shopify looks set to re-rate as cash flow strengthens, a new buyback supports the s...
Institutional appetite for bitcoin ETFs intensified, with roughly $1.15 billion flowing in over the latest week and a...
A major fund’s exit from Ocular Therapeutix raises questions about timing, liquidity, and sector signals. This articl...
Natural gas equities are delivering higher yields than broad dividend ETFs as of 2026, driven by midstream cash flows...
Tech stocks whipped around in a seesaw session as AI optimism collided with inflation concerns; the live nasdaq compo...
Even as Ethereum faces a brutal price decline, new wallet data shows ethereum more holders than Bitcoin. Analysts say...
In a dramatic 48-hour move, the world’s hottest stock market erased and then recovered a large portion of its gains, ...
Bitcoin and gold are the lone red flags so far in 2026, underscoring a rare market rotation as equities rally and tra...